Mode
Text Size
Log in / Sign up
N/A N=226 Randomized Treatment

Blast Exposed Veterans With Auditory Complaints

Hearing Impairment · Hearing Aid Fitting

Enrolled (actual)
226
Serious AEs
0.4%
Results posted
Jun 2023
Primary outcome: Primary: Hearing Handicap Inventory for Adults (HHIA) — 26.20; 37.34; 19.21 Scale score — p=.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
mild-gain hearing aids with high-frequency emphasis over 6-months (Device)
Age
Adult · 20+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Nov 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Hearing Handicap Inventory for Adults (HHIA)
26.20; 37.34; 19.21 .05
PRIMARY
Hearing Aid Benefit (Abbreviated Profile of Hearing Aid Benefit, APHAB)
-.362; -.270; -.080 .05
PRIMARY
Intent to Continue Use
9; 13; 7
SECONDARY
Hearing Aid Use Time (Number of Participants With an Average Hearing Aid Use Time of 4 Hours a Day)
9; 7; 3
SECONDARY
Speech Perception in Quiet and in Noise
.92; .93; .95; .69; .73; .72

Summary

The purpose of this study is to study blast-exposed Veterans who report hearing handicap but show normal or near normal results on standard audiometric testing. The characteristics and nature of their auditory and auditory-related skills will be examined, along with whether coexisting PTSD contributes to the hearing problems of these Veterans. In a preliminary treatment study, a sub-sample of these Veterans will be fitted with mild-gain hearing aids to determine if they benefit from low-level amplification of high-frequency sounds.

Eligibility Criteria

Inclusion Criteria

  • age 20 - 50 years; U.S. Veteran;
  • English-speaking;
  • history of blast exposure and no history of blast exposure;
  • history of PTSD and no history of PTSD;
  • self-perceived hearing handicap and no self-perceived hearing handicap;
  • normal or near normal pure tone hearing thresholds;
  • history of brain injury and no history of brain injury;
  • normal vision.

Exclusion Criteria

  • hyperacusis;
  • marked tinnitus;
  • pure tone hearing thresholds consistent with a hearing loss;
  • greater the 20/30 vision screening results (corrected or uncorrected);
  • marked speech perception deficits
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02122458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search